Clinical Trial Update: Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating INCAGN01876 in combination with immune therapies for advanced/metastatic cancers has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• INCAGN01876

Snippet

Sponsor: Incyte Biosciences International Sàrl | Conditions: Advanced Malignancies, Metastatic Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-12-28